VIRPAX PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
VIRPAX PHARMACEUTICALS INC. - More news...
VIRPAX PHARMACEUTICALS INC. - More news...
- Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
- Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
- Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
- Virpax Pharmaceuticals Announces CFO Transition
- Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
- Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
- Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
- Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
- Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
- Virpax Reports on Progress of Envelta™
- Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
- Virpax Pharmaceuticals Reports 2022 Year-End Results
- Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
- Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
- Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
- Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
- Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
- Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
- Virpax Pharmaceuticals Reports 2022 Third Quarter Results
- Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain
- Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
- Virpax Pursues OTC Medical Device Pathway for AnQlar™
- Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
- Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
- Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
- Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research
- Virpax Successfully Completes Initial Preclinical Studies for VRP324
- Virpax Pharmaceuticals Reports 2021 Year-End Results
- Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™
- Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
